



## Corrigendum

## Corrigendum to “Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib” [Leukemia Res. 79 (2019) 38–44]



Aaron T. Gerds<sup>a,\*</sup>, Tetsuzo Tauchi<sup>b</sup>, Ellen Ritchie<sup>c</sup>, Michael Deininger<sup>d</sup>, Catriona Jamieson<sup>e</sup>, Ruben Mesa<sup>f</sup>, Mark Heaney<sup>g</sup>, Norio Komatsu<sup>h</sup>, Hironobu Minami<sup>i</sup>, Yun Su<sup>j</sup>, Naveed Shaik<sup>k</sup>, Xiaoxi Zhang<sup>j</sup>, Christine DiRienzo<sup>j</sup>, Mirjana Zeremski<sup>k</sup>, Geoffrey Chan<sup>j</sup>, Moshe Talpaz<sup>l</sup>

<sup>a</sup> Leukemia and Myeloid Disorders Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA

<sup>b</sup> Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan

<sup>c</sup> Weill Cornell Medical College of Cornell University, 1300 York Ave, New York, NY 10065, USA

<sup>d</sup> Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope Dr, Salt Lake City, UT 84112, USA

<sup>e</sup> Moores Cancer Center, University of California, San Diego, 3855 Health Sciences Dr, La Jolla, CA 92093, USA

<sup>f</sup> UT Health San Antonio Cancer Center, 7979 Wurzbach Rd, San Antonio, TX 78229, USA

<sup>g</sup> Columbia University Medical Center, 630 West 168th St, New York, NY 10032, USA

<sup>h</sup> Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan

<sup>i</sup> Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan

<sup>j</sup> Pfizer Inc, 235 East 42nd St, New York, NY 10017, USA

<sup>k</sup> Pfizer Inc, 10555 Science Center Drive, San Diego, CA 92121 USA

<sup>l</sup> Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Dr, Ann Arbor, MI 48109, USA

The authors regret that there is an error in the email address of the corresponding author. Dr. Gerds' correct email address is [gerdsa@ccf.org](mailto:gerdsa@ccf.org)

[ccf.org](http://ccf.org).

The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.leukres.2019.02.012>

\* Corresponding author.

E-mail address: [gerdsa@ccf.org](mailto:gerdsa@ccf.org) (A.T. Gerds).

<https://doi.org/10.1016/j.leukres.2019.04.006>

Available online 24 April 2019

0145-2126/ © 2019 Elsevier Ltd. All rights reserved.